Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.

World J Clin Cases

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.

Published: March 2021

Background: The coronavirus disease 2019 (COVID-19) caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic. There is still no current effective guidance on the clinical management of COVID-19. Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomo-dulatory effect in COVID-19 patients.

Case Summary: We describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19.

Conclusion: MenSCs can be helpful to find a promising therapeutic approach for COVID-19.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942055PMC
http://dx.doi.org/10.12998/wjcc.v9.i7.1705DOI Listing

Publication Analysis

Top Keywords

human menstrual
8
menstrual blood-derived
8
blood-derived stem
8
stem cells
8
covid-19
7
cells immunoregulatory
4
immunoregulatory therapy
4
therapy covid-19
4
covid-19 case
4
case report
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!